T 0950/13 (Dasatinib in the treatment of chronic myelogenous leukemia/BRISTOL) of 03.02.2017

European Case Law Identifier: ECLI:EP:BA:2017:T095013.20170203
Date of decision: 3 February 2017
Case number: T 0950/13
Petition for review of: -
Application number: 04758053.5
IPC class: A61K 31/427 A61K 31/506 A61P 35/02
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: CYCLIC PROTEIN TYROSINE KINASE INHIBITORS
Applicant name: Bristol-Myers Squibb Holdings Ireland
Opponent name: APOTEX INC.
Board: 3.3.01
Headnote: -
Relevant legal provisions: European Patent Convention Art 111(1)European Patent Convention Art 83
Keywords: Main request and auxiliary request 1: Sufficiency of disclosure - (no)
Auxiliary request 2a: Sufficiency of disclosure - (yes), plausible technical concept
Appeal decision - remittal to the department of first instance (yes)
Catchword: -
Cited cases: T 0609/02 T 0157/03 T 1262/04 T 1329/04 T 0578/06
Citing cases: T 1868/16 T 0689/19 T 0699/19 T 0025/20 T 0294/20 T 1057/22 T 1125/22 T 1844/23

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the department of first instance

for further prosecution